CRL Bears Keep Retreating After Q3 Earnings Day

Charles River Laboratories International has now posted its Q3 results, and the data picture that dominated the preview note has shifted in one important direction: short sellers are continuing to cover even as options traders turn more defensive than at any point in recent weeks.

Short interest has fallen to 5.6% of the free float, down 12% across the week and 4% in the final session of November 3 alone. That extends a retreat that began from a peak around 3.6 million shares in late October. The monthly picture is more nuanced: shorts built 27% through mid-October before reversing sharply, so the bears who added into the rally have spent the past fortnight unwinding. Borrow conditions give them no reason to stay: availability has opened up dramatically, now at 712%, compared to a 52-week low of 387%. Cost to borrow is just 0.46%, close to its lowest reading in months. The lending market is loose, and there is no mechanical pressure forcing the remaining short position to close.

Options positioning tells a different story, and the contrast is worth flagging. The put/call ratio has jumped to 0.54, more than two standard deviations above its 20-day average of 0.40. That is the most defensively positioned the options market has been in the recent period, even as the 52-week high of 1.47 shows how much further hedging activity could go. The spike in the PCR came on the same day as a 3.9% single-day gain to $351.87, a combination that suggests some investors are buying protection into strength rather than chasing the move outright. The stock is still down just under 2% across the week, with the Q3 earnings day itself coinciding with the strongest single-day bounce.

The Street entered the print with a constructive lean that the stock has now exceeded. The mean price target from analysts, as of late October, was $314, well below the current price of $352. Morgan Stanley raised its target to $340 in mid-October, maintaining Overweight, while UBS reinstated coverage with a Buy and a $357 target around the same time. A cluster of firms including Jefferies, Deutsche Bank, TD Cowen, Barclays, and Baird all lifted targets in late September, most landing in the $320 to $340 range. With the stock now trading above nearly every published target, the bulls' case rests on the operational story: 5% to 7% organic revenue growth through 2030, a push above 27% DSA operating margins, and a pricing and automation cycle in Manufacturing that management has flagged as the highest-margin opportunity. Bears counter that biopharma consolidation and customer in-sourcing remain live threats, and that the FDA's accelerating acceptance of non-animal testing methods puts the highest-margin DSA business at structural risk over a longer horizon.

The institutional register is broadly stable. FMR holds just over 10% and added meaningfully in the most recent quarter. Invesco disclosed a 6.2% passive stake in August, up from 4.9% previously. T. Rowe Price added around 380,000 shares to bring its position to 3.2% of shares, the most notable active-manager move in the recent data. No 13D activists are on the register. The insider picture is dominated by pre-arranged 10b5-1 plan activity: James Foster, now a director, exercised options and sold shares twice in the past few months, the most recent being a $8.4 million sale at $350 on October 22. The CFO made a small discretionary open-market purchase of $2,974 at $297 in September, the only unplanned buy in the recent record. Net insider selling over 90 days runs to roughly $35 million, though the structured nature of the Foster transactions limits how much signal to draw from that figure.

With Q3 now behind it and the next earnings event not until mid-February 2027, the near-term focus shifts to whether the stock can hold above the analyst consensus range, and whether the defensive options activity from November 3 proves to be one-day hedging or the start of a broader reassessment of a stock that has run 21% in a month.